Alfred Berkeley Joins BioMark’s Advisory Team

Vancouver, British Columbia – (January 11, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is glad to announce Alfred Berkeley as a new member of the BioMark’s Advisory team as he will be providing strategic and financial advice to help expand the company’s commercialization effort in the U.S.

 

Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Mr. Berkeley join our advisory group at this moment. Mr. Berkeley brings years of experience and a deep knowledge of both financial and business development activities in the U.S. His past support and continued counsel are greatly appreciated, and his extensive experience and connections will be invaluable as BioMark moves to make a committed effort to instigate commercialization and expand its clinical research collaborations in the U.S.”

BioMark’s board and shareholders welcome Mr. Berkeley and look forward to his professional contribution to building BioMark into a stronger international entity with an operating base in North America.

 

About Alfred Rives Berkeley III

 

Mr. Alfred Rives Berkeley, III, has over 40 years of experience in the financial industry, and currently serves as the Chairman at Princeton Capital Management, Inc., since January 2013, a position he previously held from 1996 to 2006. He currently serves as Chairman of the Board at Noxilizer, Inc., and has been a Director of RealPage, Inc since 2003. He is also a member of the Board of Visitors of the School of Medicine of the University of Maryland and has served as a Trustee of the Johns Hopkins University, the Nature Conservancy, and the Mathematical Sciences Research Institute.

Mr Berkeley started his career by joining Alex Brown & Sons in 1972 as a Research Analyst, and became General Partner there in 1983, Head of Information Services in 1985, moved on to the Merger and Acquisition department in 1987, and became Managing Director and Senior Banker in the Corporate Finance. Between 1996 and 2000, Mr. Berkeley was President of the NASDAQ Stock Market, Inc., after which he was named Vice-Chairman until 2003.

Mr. Berkeley has also served as a member of numerous government advisory panels including The President’s National Infrastructure Advisory Council and the Monetary Authority of Singapore’s International Advisory Council. He was appointed to the National Infrastructure Assurance Council by President George W. Bush.

He has also been a Director of a number of public and private companies, institutions, and non-profit organizations including Policy Management Systems, Comshare, Cognos, ACI Worldwide, Edgar Online, Noxilizer, Inc., Security First Corp., Gentag, Inc., ViiNet, Inc., Differential Dynamics, Inc., The Nature Conservancy, WebEx Communication, Inc., Policy Management Systems Corporation, The World Economic Forum USA, and Johns Hopkins University.

Mr. Berkeley has served as Captain in the US Air Force from 1968 to 1972 and officer in the US Air Force Reserve and earned his M.B.A. from the Wharton School and a BA in English from the University of Virginia.

Press Release – Alfred Berkeley Joins BioMark’s Advisory Team

BIOMARK RETAINS QUESTRADE, INC. TO PROVIDE MARKET MAKING SERVICES

Vancouver, British Columbia – (December 7th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that it has retained Questrade, Inc. (“Questrade”) to provide market-making services in accordance with CSE guidelines.

 

The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either party may terminate the agreement with 30 days written notice. Though BioMark and Questrade are unrelated and unaffiliated entities and Questrade will not receive shares or options as compensation from the Company, Questrade and its clients have or may have a direct interest in the securities of BioMark.

 

About Questrade, Inc.

 

Questrade, Inc., provides Canadians with high-speed, direct access trading in the U.S. and Canadian stock and options markets through its IQ trading platforms. Questrade offers market making services on behalf of TSX, TSX Venture Exchange, and Canadian Securities Exchange listed companies, providing liquidity on the stock exchanges for shareholders.

Press Release -BIOMARK RETAINS QUESTRADE, INC. TO PROVIDE MARKET MAKING SERVICES

BIOMARK SCIENTIFIC ADVISOR DR. DONALD MILLER TO PRESENT AT THE DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP

Vancouver, British Columbia – (September 23rd, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark’s SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG).

 

Rashid Ahmed, President and CEO of BioMark, says, “We are pleased to have Dr. Donald Miller present his important work on the SSAT amantadine assay for the early detection of cancer in such an excellent forum with the distinguished Delaware Valley Drug Metabolism Discussion Group. Don’s work on biomarkers and the blood-brain barrier, as relates to cancer, is a crucial part of BioMark’s mission to use biomarkers to diagnose and monitor cancers early. His talk will increase BioMark’s visibility to companies in the Biopharma and diagnostics space and will further support the scientific foundation of BioMark’s technology platform.”

 

The DVDMDG takes place online on September 22 and September 29, Eastern time. Dr. Miller is presenting on September 29 at 2pm. For more information, please refer to the DVDMDG website at: https://www.dvdmdg.org/

 

About Dr. Donald Miller

Dr. Donald Miller is a Professor in the Department of Pharmacology and Therapeutics at the University of Manitoba. He received his B.Sc. in Chemistry from Bethel College (1985), Newton, Kansas, and his Ph.D. in Pharmacology and Toxicology from the University of Kansas (1991). He was a Marion Merrell Dow Postdoctoral Research Fellow in Dr. Ronald Borchardt’s laboratory at the University of Kansas where he studied biological approaches for enhancing drug delivery and drug absorption (1991-1993). Dr. Miller is an internationally recognized expert in drug transporters and blood-brain barrier function, having served on both NIH and CIHR grant and fellowship review panels, as well as reviewer and site visit examiner for Austrian and European Union based program grant initiatives. Dr. Miller’s research program includes examination of blood-brain barrier changes during brain tumor development and identification of methods for increasing the delivery of chemotherapeutic agents to brain tumor; identification and characterization of drug efflux transport proteins in the blood-brain barrier and the molecular mechanisms influencing activity and expression; and the design and development of nanoparticle drug delivery platforms for CNS applications.

 

About the Delaware Valley Drug Metabolism Discussion Group (DVDMDG)

The DVDMDG provides scientists with a forum to discuss current topics in the drug metabolism sciences and includes scientists from most of the major pharmaceutical companies in the Philadelphia area as well as many local universities and laboratories. The continued growth of the organization since its founding in 1975 attests to the relevance and utility of the group.

Press Release – BIOMARK SCIENTIFIC ADVISOR DR. DONALD MILLER TO PRESENT AT THE DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP

BIOMARK APPOINTS DR. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC

Vancouver, British Columbia – (September 16th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team.

Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Haince into our advisory team. Jeff brings a pragmatic perspective to our bench strength along with a thorough understanding of engaging within the vibrant biotech ecosystem in Quebec and North America.  Jeff’s business and product development expertise with diverse medical, scientific, and business experience applied to strategic planning and innovation management in both academia and biotech industry are important for commercialization of BioMark’s disruptive cancer assays.  Jeff possesses a good understanding of the whole value chain and regulatory landscape in the pharmaceutical/healthcare industry and played a vital role in the commercialization of 2 early cancer detection molecular diagnostics.”

 

About Dr. Jean-Francois Haince

Dr. Haince holds a PhD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. He cumulates over 15 years of experience in cancer research and authored over 20 peer-reviewed scientific publications. During his term at DiagnoCure from 2007 to 2015, he has been responsible for the development of new molecular diagnostic tests from product design to clinical validation.  Dr. Haince currently manages a multidisciplinary team of experts at SOVAR, providing advice and project management support to development and deployment of technological innovations stemming from cutting-edge research. He also sits on the Research and Innovation Committee at the l’Institut National du Sport du Québec, advising the Institut’s scientific director on all issues related to its scientific and technical activities.

 

Press Release – BIOMARK APPOINTS Dr. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC